Yannis Hamidou | Immunotherapy |

Mr. Yannis Hamidou | Immunotherapy | Best Researcher Award

Yannis Hamidou at Amiens Picardie University Hospital | France

Mr. Yannis Hamidou is a dedicated rheumatologist currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, France. With a strong academic background in medical sciences, rheumatology, and sports medicine, he has actively contributed to clinical research focusing on autoimmune and inflammatory diseases. His expertise spans therapeutic innovations, patient-centered care, and multidisciplinary collaborations aimed at improving outcomes in rheumatology and intensive care settings. Through his clinical practice and research endeavors, Mr. Hamidou has developed a reputation for excellence in precision treatment strategies and evidence-based medicine, significantly impacting rheumatology healthcare and contributing to advancements in patient management practices.

Publication Profile 

Orcid

Education 

Mr. Yannis Hamidou completed his postgraduate diploma in medical sciences, laying the foundation for his medical career. He successfully defended his medical thesis , advancing his academic and clinical expertise. To specialize further, he obtained a postgraduate diploma in rheumatology, focusing on autoimmune and inflammatory disorders. Additionally, he completed a specialization in sports medicine and earned the BPC certification, broadening his clinical competencies. This comprehensive academic training has equipped him with extensive knowledge across internal medicine, rheumatology, and sports-related healthcare, preparing him for leadership roles in clinical care, research, and education.

Experience 

Mr. Yannis Hamidou is currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, where he integrates clinical care with research responsibilities. His work in intensive care medicine includes serving as Principal Investigator for an observational clinical study, focusing on chronic inflammatory diseases in critical care settings. Alongside his clinical duties, he actively participates in developing patient-specific treatment strategies for autoimmune and rheumatologic disorders. His multidisciplinary experience spans rheumatology, sports medicine, and internal medicine, providing comprehensive care solutions. He also contributes to academic teaching and mentoring, fostering evidence-based clinical practices while engaging in ongoing research aimed at improving patient outcomes.

Awards and Honors 

Mr. Yannis Hamidou academic achievements and clinical leadership reflect his professional excellence. His appointments, including Clinic Chief Assistant at CHU Amiens-Picardie and Principal Investigator roles in clinical studies, highlight his recognition within the medical community. His selection for advanced training in rheumatology, sports medicine, and critical care research further emphasizes his commitment to advancing medical science. Future recognitions are anticipated as his contributions to rheumatology research, patient care innovations, and academic scholarship continue to grow, positioning him as a promising leader in the field of rheumatology and clinical medicine in France.

Research Focus 

Mr. Yannis Hamidou research primarily targets autoimmune and inflammatory disorders, with a focus on therapeutic innovations and patient outcome optimization. His work in rheumatology explores the long-term maintenance of advanced therapies like Janus kinase inhibitors and investigates biomarkers such as fecal calprotectin for early disease detection. Additionally, he has contributed to understanding mortality causes in intensive care settings among patients with chronic inflammatory diseases. By integrating real-world data and observational clinical research, his studies aim to refine diagnostic precision, enhance treatment strategies, and inform evidence-based clinical guidelines, ultimately improving healthcare delivery for patients with complex rheumatologic conditions.

Publication Top Notes

Dr. Marc Bender|Immunotherapy |Best Researcher Award

Dr. Marc Bender|Pharmaceutical Chemistry |Best Researcher Award|

Dr. Marc Bender at abriz University of Medical Sciences, Iran

PROFILE  

orcid

Early Academic Pursuits 📚

Marc Bender’s academic journey began with a strong foundation in molecular biology, earning a (link unavailable) and (link unavailable) from Universität Hamburg. He furthered his expertise by pursuing a doctorate in skin cancer research at the department of dermatology, Elbe Klinikum Buxtehude. His thesis focused on elucidating molecular mechanisms, particularly epigenetic regulation via miRNAs, involved in tumor progression of cutaneous squamous cell carcinoma.

Professional Endeavors 💼

As a data scientist, Marc contributed to the European melanoma registry (EUMelaReg), evaluating retrospective data for real-world clinical trials. This experience deepened his understanding of melanoma and immunotherapy, and he developed skills in statistical methods and programming. His professional endeavors have been marked by a commitment to advancing cancer research and treatment.

Contributions and Research Focus 🔬

Marc’s research focus encompasses various aspects of skin cancer, including:

– Investigating effects of combined UVA, UVB, visible light, and infrared radiation on human skin cells (KAUVIR)
– Examining the influence of UVA and UVB irradiation on human dermal stem cells (UV-DHDS)
– Comparing treatments for melanoma, including anti-PD1 monotherapy and BRAF/MEK inhibitor treatment (PDSeq and EMRSeq)
– Analyzing immune checkpoint inhibitor maintenance treatment after achieving a partial or complete response (EUMelaReg)

Accolades and Recognition 🏆

Marc’s work has been recognized through publications in esteemed journals, including:

– Journal of Cancer Research and Clinical Oncology
– Journal of Photochemistry and Photobiology B Biology
– Cancers (MDPI)
– Journal of Clinical Oncology (conference paper)
– Annals of Oncology (conference paper)

Impact and Influence 🌟

Marc’s research has contributed significantly to the understanding of skin cancer mechanisms and treatment options. His work has:

– Advanced knowledge of miRNA expression and its association with tumor progression
– Investigated treatment adherence in patients with stage III melanoma
– Compared outcomes of different treatment approaches for metastatic melanoma

Legacy and Future Contributions 🌱

As a dedicated researcher, Marc continues to contribute to the field of skin cancer research. His future endeavors will likely focus on:

– Furthering understanding of molecular mechanisms in skin cancer
– Developing innovative treatment approaches
– Collaborating with international researchers to advance cancer research

Marc’s legacy will be marked by his commitment to advancing cancer research, improving treatment options, and enhancing patient outcomes. His work will continue to influence the scientific community, inspiring future generations of researchers.

🎓Publication 

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

  • Authors   : Marc Bender
  • Journal    :Cancers
  • Year         :2022

UVB damage response of dermal stem cells as melanocyte precursors compared to keratinocytes, melanocytes, and fibroblasts from human foreskin

  • Authors   :Marc Bender
  • Journal    :Photochemistry and Photobiology B: Biology
  • Year         :2021

UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines

  • Authors   : Marc Bender
  • Journal    :Cancer Research and Clinical Oncologyy
  • Year         :2020